385 related articles for article (PubMed ID: 19368776)
1. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
3. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
[TBL] [Abstract][Full Text] [Related]
4. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
6. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
7. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
8. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
[TBL] [Abstract][Full Text] [Related]
9. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
[TBL] [Abstract][Full Text] [Related]
10. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
11. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
12. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
14. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
15. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
Motavalli Khiavi F; Arashkia A; Golkar M; Nasimi M; Roohvand F; Azadmanesh K
J Immunol Res; 2018; 2018():9464186. PubMed ID: 29854852
[No Abstract] [Full Text] [Related]
16. Optimization of multimeric human papillomavirus L2 vaccines.
Jagu S; Kwak K; Karanam B; Huh WK; Damotharan V; Chivukula SV; Roden RB
PLoS One; 2013; 8(1):e55538. PubMed ID: 23383218
[TBL] [Abstract][Full Text] [Related]
17. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
[TBL] [Abstract][Full Text] [Related]
18. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
19. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
